万孚生物(300482) - 2025 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit of approximately 46 million to 69 million CNY for 2025, representing a decline of over 50% compared to the previous year[4]. - The net profit attributable to shareholders is projected to decrease by 91.81% to 4.6 million CNY, down from 56.16 million CNY in the same period last year[5]. Revenue and Market Trends - The company's main business revenue has declined, primarily due to a drop in domestic income influenced by VAT rate adjustments and medical industry policies[7]. - The gross profit margin has decreased due to price reductions in the domestic market and changes in product structure, alongside high R&D and sales expenses to maintain competitiveness[8]. - The overseas market has shown steady growth, with an increase in market share in small laboratories and a long-term supply agreement with a major U.S. client for respiratory products[9]. Product Development and Innovation - The company has launched several new products, including the MiniTLA LA-6400 automatic biochemical immunoassay line and a series of respiratory infection test kits, which are expected to enhance operational efficiency and market presence[9]. - The company is focusing on digitalization and AI projects, with a successful application for an AI-assisted analysis software for coagulation disorders, marking a strategic breakthrough in AI healthcare[10]. - The company plans to continue its customer-oriented approach, driven by innovation and AI, to significantly improve business performance in 2026[10]. Future Outlook - For 2026, the company aims to leverage market recovery and expand its presence in both domestic and overseas markets, particularly in North America, while enhancing its innovation capabilities[10]. - Financial data presented is preliminary and has not been audited, with detailed figures to be disclosed in the 2025 annual report[11].